Trial Profile
Phase 1 Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 24 May 2018
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Volasertib (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 20 Dec 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Jan 2016 New trial record